Paliperidone Teva (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone Teva, is a long‑acting atypical antipsychotic presented as an injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients and for maintenance therapy to reduce relapse risk.

GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone Teva is a long‑acting injectable antipsychotic that works within the schizophrenia treatment pathway. - Schizophrenia: Improves psychotic symptoms and helps maintain stability over time. - Schizoaffective disorder: Reduces mood‑related and psychotic episodes when used as maintenance therapy. - Bipolar I disorder (maintenance): Assists in preventing recurrence of manic or depressive episodes as an adjunct to mood stabilisers.

Paliperidone Teva may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness (akathisia) - Constipation

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, Parkinsonism) - Neuroleptic malignant syndrome - Hyperglycaemia or new‑onset diabetes - Orthostatic hypotension - Seizures - Tardive dyskinesia

When prescribing Paliperidone Teva, clinicians should consider several safety aspects. - Cardiovascular assessment: Evaluate for QT‑prolongation risk and monitor ECG where indicated. - Metabolic monitoring: Check fasting glucose and lipid profile regularly. - CNS effects: Advise patients about potential sedation and impaired coordination. - Pregnancy and lactation: Use only if the benefit outweighs potential risk to the fetus or infant. - Drug‑interaction review: Assess concomitant medications for additive CNS depression. - Store at ambient temperature: keep in original container, protect from moisture and light.

Paliperidone Teva can interact with other medicines that influence its pharmacokinetics or pharmacodynamics.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (strongly increase paliperidone levels). - QT‑prolonging agents: combined risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluoxetine). - CNS depressants (e.g., benzodiazepines) may enhance sedation. - Antihistamines,   - Antihistamines   -